Immune Regulation by Regnase‐1 and Related Endoribonucleases
- 1Department of Medical Chemistry Graduate School of Medicine Kyoto University Kyoto Japan
Abstract
Regnase‐1 (ZC3H12A) is a stem‐loop (SL)‐recognizing endoribonuclease that couples immune stimulation to selective mRNA decay. Although originally characterized as a negative regulator of inflammatory cytokine expression, recent studies have expanded this view by placing Regnase‐1 within a broader network of SL‐recognizing RNA decay factors, including Roquin proteins and Regnase‐3, and by revealing context‐dependent functions in immune and nonimmune cells. Through regulation of transcripts encoding cytokines, costimulatory molecules, and transcriptional regulators, Regnase‐1 restrains innate and adaptive immune activation, but biological output varies according to cell type, tissue environment, disease stage, and mode of perturbation. In T cells, including engineered T cells used in adoptive cell therapy, Regnase‐1 inhibition can enhance antitumor activity in preclinical models, whereas in epithelial tissues Regnase‐1 can limit inflammatory circuits that affect host defense, tissue injury, and inflammation‐associated tumorigenesis. Structure‐targeting antisense oligonucleotides and genome‐editing approaches have further raised the possibility of therapeutically modulating Regnase‐dependent RNA decay. In this Review, we discuss molecular mechanisms of Regnase‐1‐mediated mRNA decay, context‐dependent functions across tissues and diseases, and the opportunities and limitations of targeting this pathway therapeutically.
Related
- Identification of small-molecule inhibitors of the immune system repressor Regnase-1.
- Extracellular vesicles in the immune regulation of hematological malignancies: mechanisms, prognostic significance, and therapeutic opportunities
- Progress in the Study of B-Cell Immune Metabolic Regulation Mechanisms in Exercise-Induced Fatigue: A Narrative Review
- Gut microbiota-bile acid-immune axis: receptor signaling, metabolic regulation, and therapeutic translation
- Short-Chain Fatty Acids as Modulators of the Gut–Immune Axis in Inflammatory Bowel Disease: Linking Metabolism, Immune Regulation, and Epithelial Barrier Function
BibTeX
@article{uehata2026immune,
title = {{Immune Regulation by Regnase‐1 and Related Endoribonucleases}},
author = {Takuya Uehata and Osamu Takeuchi},
journal = {European Journal of Immunology},
year = {2026},
month = nov,
doi = {10.1002/eji.70313},
url = {https://doi.org/10.1002/eji.70313},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Immune Regulation by Regnase‐1 and Related Endoribonucleases
AU - Takuya Uehata
AU - Osamu Takeuchi
PY - 2026
DA - 2026/11/04
JO - European Journal of Immunology
DO - 10.1002/eji.70313
UR - https://doi.org/10.1002/eji.70313
AB - Regnase‐1 (ZC3H12A) is a stem‐loop (SL)‐recognizing endoribonuclease that couples immune stimulation to selective mRNA decay. Although originally characterized as a negative regulator of inflammatory cytokine expression, recent studies have expanded this view by placing Regnase‐1 within a broader network of SL‐recognizing RNA decay factors, including Roquin proteins and Regnase‐3, and by revealing context‐dependent functions in immune and nonimmune cells. Through regulation of transcripts encoding cytokines, costimulatory molecules, and transcriptional regulators, Regnase‐1 restrains innate and adaptive immune activation, but biological output varies according to cell type, tissue environment, disease stage, and mode of perturbation. In T cells, including engineered T cells used in adoptive cell therapy, Regnase‐1 inhibition can enhance antitumor activity in preclinical models, whereas in epithelial tissues Regnase‐1 can limit inflammatory circuits that affect host defense, tissue injury, and inflammation‐associated tumorigenesis. Structure‐targeting antisense oligonucleotides and genome‐editing approaches have further raised the possibility of therapeutically modulating Regnase‐dependent RNA decay. In this Review, we discuss molecular mechanisms of Regnase‐1‐mediated mRNA decay, context‐dependent functions across tissues and diseases, and the opportunities and limitations of targeting this pathway therapeutically.
SN - 0014-2980
SN - 1521-4141
ER -